{"nctId":"NCT01277211","briefTitle":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","startDateStruct":{"date":"2011-09-19","type":"ACTUAL"},"conditions":["Contraception"],"count":983,"armGroups":[{"label":"ENG-EE (NuvaRing)","type":"EXPERIMENTAL","interventionNames":["Drug: ENG 120 µg + EE 15 µg intravaginal ring"]},{"label":"DRSP-EE","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DRSP 3 mg + EE 30 µg"]}],"interventions":[{"name":"ENG 120 µg + EE 15 µg intravaginal ring","otherNames":["NuvaRing"]},{"name":"DRSP 3 mg + EE 30 µg","otherNames":["Yasmin"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Sexually active Chinese women, at risk for pregnancy and not planning to use condoms during trial medication use\n* Women in need for contraception and willing to use a hormonal contraceptive method for 13 cycles\n* Body mass index ≥18 and ≤29 kg/m\\^2\n\nKey Exclusion Criteria:\n\n* Contraindications for contraceptive steroids\n* Abnormal cervical smear corresponding to indeterminate changes at screening\n* Clinically relevant abnormal laboratory result at screening as judged by the investigator.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pearl Index, by Treatment Group","description":"Primary Efficacy Outcome measure for this study was contraceptive efficacy, or the prevention of in-treatment pregnancy. The total incidence of in-treatment pregnancies was expressed as the Pearl Index, which is defined as the number of in-treatment pregnancies per 100 woman-years of exposure (one woman-year defined as a period of 365.25 days).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":null},{"groupId":"OG001","value":"3.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Intermenstrual (Breakthrough) Bleeding/Spotting, by Cycle","description":"Participants kept diaries to record vaginal bleeding events. They were asked to record, on a daily basis, whether they experienced vaginal bleeding, which included BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. (This is also known as \"breakthough\" bleeding.) Vaginal bleeding that required \\>=2 pads/tampons per day was classified as BLEEDING. Vaginal bleeding that required \\<=1 pad/tampon per day was classified as SPOTTING.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"21.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Absence of Withdrawal Bleeding, by Cycle","description":"Participants kept diaries to record vaginal bleeding events. They were asked to record, on a daily basis, whether vaginal bleeding was present. Absence of withdrawal bleeding was defined as no bleeding/spotting during the expected bleeding period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":714},"commonTop":[]}}}